LST News
The push to digitize healthcare has been going on for at least 10 years—that’s when the push began for hospitals and physicians to implement electronic health records. Now, providers are looking for ways to achieve measureable results with the systems they have in place. Health Data Management has compiled a variety of predictions from sources, and here are the 12 trends that we expect to dominate healthcare IT in the New Year.
But with signs of slower economic activity in the U.S. and China, continuing uncertainty over the U.K.’s future in the European Union, and unresolved issues surrounding the delivery of healthcare and especially the price of treatments, it remains to be seen whether 2019 will be as good a year for biopharma as 2018 has been in many ways. Below is a list of five biopharma-related trends as articulated by experts and others with a stake in the industry, as articulated in interviews with GEN, or in reports and other public statements in recent weeks.
We saw a major milestone in FDA approvals in 2018, but a political deadlock that led to a partial government shutdown before Christmas could take some of the shine off a golden year. Scott Gottlieb, M.D., FDA commissioner and President Donald Trump’s pick for the job, took to Twitter over the holidays after the shutdown took effect on Dec. 22, showing those FDA staffers still turning up to work. But he admits the ongoing political disagreements in Washington are hampering some drug review efforts, tweeting on Dec. 29: “Many asked if #FDA can accept new medical product applications during the shutdown. The #FDA can't collect FY 2019 user fee payments during the shutdown, which means we can't accept new applications for products under user fee programs: PDUFA, GDUFA, BsUFA, MDUFA, ADUFA, AGDUFA."
